VERITAS  study  
PI: [INVESTIGATOR_266548], MD  
 CONFIDENTIAL
 
 
 
 
 
  
VERITAS  
 
 
 
 
THO [ZIP_CODE]: Na Vigation  Endoscopy to  Reach Indeterminate lung nodules 
versus  Transthoracic needle  Aspi[INVESTIGATOR_1516], a randomized controlled S tudy (VERITAS)  
 
 
Principal Investigator: 
[INVESTIGATOR_266548], MD  
Professor of Medicine and Thoracic Surgery  
Associate Professor of Mechanical Engineering  
Vanderbilt University School of Medicine  
 
Co-Principal Investigator: 
[INVESTIGATOR_266549] M Rahman DPhil MSc FRCP  
Professor of Respi[INVESTIGATOR_266550], Oxford Respi[INVESTIGATOR_266551] 29MAR2023 
 
     
 
 
 
                                                      
 

   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
2 of 38 
 PROTOCOL SYNOPSIS  
 
Title  NaVigation  Endoscopy to  Reach Indeterminate lung nodules versus  Transthoracic 
needle  Aspi[INVESTIGATOR_1516], a randomized controlled Study 
Short title  VERITAS  
Study objective  In this study, we propose to study in a 1:[ADDRESS_324472] with fluoroscopic 
navigation (F -Nav)  using a non- inferiority study design (primary endpoint) versus 
the current clinical standard of care: CT -guided biopsy.  
Study device  SuperDimension and Fluoroscopic navigation . 
Design  Multicenter, randomized, non -inferiority study . 
Study centers  Vander bilt University Medical Center, and approximately 5 to 7 additional sites 
based in the [LOCATION_002].  
Number of subjects  N=[ADDRESS_324473] follow -up Patients with non -diagnostic biopsy or benign diagnoses will be followed for up to 
one year as part of the study  with further diagnostic procedures as clinically 
required . 
Inclusion  
criteria  1. ≥ 18 years  of age  at time of signing informed consent .  
2. Referred for biopsy of a single indeterminate pulmonary nodule , with the 
following characteristics regarding size, location, accessibility, and 
probability of malignancy:   
a) Intermediate or high pre-test probability of malignancy as defined by a 
pre-test probability of malignancy between 10% and 100%, using a 
validated clinical prediction model , which is either:  
i. The Brock model if no PET scan data are available , or  
ii. The Herder model if PET -CT data are available.  
b) Size between 10  and 30 mm  (long diameter).  
c) Location peripheral , here defined as occupying the middle or outer 
third lung zones . 
d) Accessible via navigation bronchoscopy and also accessible via CT -
guided biopsy (i.e. the nodule is clinically suited to equal access by 
[CONTACT_266570]), as confirmed by [CONTACT_266571] 
(see Section 4.5).  
Exclusion  
criteria  1. Patients  with proximal nodules, as defined by [CONTACT_266572] (endobronchial lesions) or linear endobronchial 
ultrasound will not be eligible for the study (as these patients would 
standardly undergo bronchoscopy already).  
2. Patient s with multiple nodules requiring biopsy (patients may have other 
nodules not considered for biopsy) . 
3. Radiologically abnormal mediastinal or hilar lymph nodes requiring endobronchial ultrasound . 
4. Patients for whom stereotactic body radiation therapy is plan ned even if 
biopsies show no evidence of malignancy.  
5. Patients with contraindication to biopsy or deep sedation/general anesthesia . 
6. Patients unable  or unwilling to comply with study follow -up schedule . 
7. Patients previously randomized to the study.  
8. Patients unable to provide documented informed consent . 
9. Patients who are pregnant or nursing . 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324474] (navigation bronchoscopy) to the CT -guided biopsy 
pathway. Definitive diagnoses are pre -defined as any of the following:  
• Malignancy on histology , OR 
• Biopsies with abnormal tissue (excluding  normal or absence of lung 
paren chyma ) that are followed by a surgical lung biopsy yielding the same 
histological diagnosis, OR 
• Specific benign histopathologic finding which accounts for the presence of 
a lung nodule (specifically including organizing pneumonia, frank 
purulence, granulomatous inflammation , or other specific benign finding) 
AND 
• Absence of malignancy (true negative) through 1-year  longitudinal CT 
follow -up, defined as : 
o The nodule markedly regress es or resolves on follow -up imaging, 
OR 
o a persistent nodule has not been diagnosed as malignant , AND  
o there are no plans for repeat invasive diagnostic procedure s 
through 12 months  follow -up.  
 
Biopsies with normal or absence of lung parenchyma , atypia and non-specific 
inflammation  will be considered non-diagnostic. All biopsies not diagnostic of 
malignancy (from both arms) will be centrally reviewed by a n independent expert 
lung pathologist blinded to the biopsy technique , and follow -up diagnosis will be 
established during routine clinical follow -up after 1 year.  
Secondary  
endpoints • Rate of pneumothorax . 
• Rate of pneumothorax requiring chest tube placement . 
• Clinically significant bleeding (defined by [CONTACT_266573]).   
• Need for hospi[INVESTIGATOR_266552] . 
• Duration of the procedure . 
• Procedural factors associated with improved yield (type of biopsy, number of biopsies , use of radial ultrasound, presence of a bronchus sign, biopsy 
site). 
• Need for additional nodule biopsy.  
• Need for additional procedure for staging . 
• Radiation exposure from fluoroscopy -guided bronchoscopy and CT for 
CT-guided biopsy . 
• Need for F -Nav during navigation bronchoscopy.  
• Diagnostic yield, defined as the rate at which histopat hology is obtained 
which explains the presence of a nodule (according to definitions set forth 
for the primary endpoint) and permits post-biopsy clinical decision -
making without  need for immediate additional diagnostic procedures.  
• Rate at which the biopsy procedure yields a confident clinical diagnosis 
(including any added yield from endobronchial ultrasound-guided 
mediastinal and/or hilar lymph node biopsies  or microbiologic stu dies 
which yield an explanation for a nodule despi[INVESTIGATOR_266553]-diagnostic biopsy 
specimens).  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324475] -guided biopsy is 
90%. The non- inferiority margin is set at 10 percentage points, and one -sided type I 
error rate is set at 5%. Thus, if the true diagnostic accuracy  for navigation 
bronchoscopy is lower than 80%, we will have 5% probability (type I e rror rate) to 
incorrectly conclude noninferiority.  
Interim  
analysis  No interim analyses are planned for this trial.  
 
  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
5 of 38 
 Table of Contents  
1. General Study Information  ......................................................................................................................... 8 
2. Statement of compliance ............................................................................................................................. 8 
3. Purpose of the study ................................................................................................................................... 8 
3.1 Hypothesis  ................................ ................................ ................................ ................................ ........................  8 
3.2 Aims and Objectives  ................................ ................................ ................................ ................................ .........  9 
4. Study Design ............................................................................................................................................ 10 
4.1 General Study Design  ................................ ................................ ................................ ................................ ....... 10 
4.2 Patient Inclusion and Exclusion Criteria  ................................ ................................ ................................ ............ 10 
4.3 Withdrawal of Patients  ................................ ................................ ................................ ................................ ....11 
4.4 Patient Flow  ................................ ................................ ................................ ................................ .................... 12 
4.5 Image Transfer and Interventional Panel Adjudi cation  ................................ ................................ ..................... 12 
4.6 Intervention Arm: Bronchoscopy Pathway  ................................ ................................ ................................ ....... 14 
4.7 Comparison: CT -guided Biopsy Pathway  ................................ ................................ ................................ .......... 14 
4.8 Outcomes  ................................ ................................ ................................ ................................ ........................ 15 
4.9 Centralized Pathology Review (Core Lab Confirmation)  ................................ ................................ .................... 16 
4.10 Study Flow  ................................ ................................ ................................ ................................ ....................... 16 
5. Enrollment Procedures .............................................................................................................................. 16 
6. Methodology ............................................................................................................................................ 18 
6.1 Statistical methodology  ................................ ................................ ................................ ................................ ...18 
6.2 Analysis plan  ................................ ................................ ................................ ................................ .................... 19 
6.3 Variables Recorded  ................................ ................................ ................................ ................................ .......... 21 
7. Safety Reporting of Adverse Events  ......................................................................................................... 21 
7.1 Grading ................................ ................................ ................................ ................................ ............................ 21 
7.2 Reporting Period ................................ ................................ ................................ ................................ .............. 22 
7.3 Procedure -related Risks  ................................ ................................ ................................ ................................ ...23 
7.4 Research -only Risks  ................................ ................................ ................................ ................................ ......... 24 
7.5 Benefits  ................................ ................................ ................................ ................................ ........................... 24 
7.6 Definitions  ................................ ................................ ................................ ................................ ....................... 24 
7.6.1  Adverse Event (AE)  ................................ ................................ ................................ ................................ ..24 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
6 of 38 
 7.6.2  Serious Adverse Event (SAE)  ................................ ................................ ................................ .................... [ADDRESS_324476] Keepi[INVESTIGATOR_007]  ................................ ................................ ................................ .................. 28 
9. Regulatory Considerations  ........................................................................................................................ 28 
9.1 Protocol Review and Amendments  ................................ ................................ ................................ .................. 28 
9.2 Informed Consent  ................................ ................................ ................................ ................................ ............ 29 
9.3 Ethics and Good Clinical Practice ................................ ................................ ................................ ...................... 29 
9.4 Confidentiality  ................................ ................................ ................................ ................................ ................. 30 
9.5 Payment and Remuneration  ................................ ................................ ................................ ............................ 30 
9.6 Costs  ................................ ................................ ................................ ................................ ............................... 30 
9.7 Study Termination  ................................ ................................ ................................ ................................ ........... 30 
10. Study Coordination  ............................................................................................................................... 30 
10.1 Trial Compliance  ................................ ................................ ................................ ................................ .............. 30 
10.2 Changes to Protocol and Informed Consent Document  ................................ ................................ .................... 31 
10.3 Protocol Deviations  ................................ ................................ ................................ ................................ ......... 31 
10.4 Monitoring and Quality Assurance  ................................ ................................ ................................ ................... 31 
10.5 Data Verification  ................................ ................................ ................................ ................................ .............. 31 
10.6 Study Documentation  ................................ ................................ ................................ ................................ ......32 
10.7 Closure of the Study  ................................ ................................ ................................ ................................ ........ 32 
10.8 Recor ds Retention  ................................ ................................ ................................ ................................ ........... 32 
11. Publications  .......................................................................................................................................... 32 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
7 of 38 
 12. References  ............................................................................................................................................ 34 
13. CONSORT Flow Diagram  .................................................................................................................... 35 
14. Procedural Flow Chart  .......................................................................................................................... 36 
15. Screening Flow Chart  ............................................................................................................................ 37 
16. Study Assessment Table ........................................................................................................................ 38 
 
  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
8 of 38 
 1. General Study Information  
 
Principal Investigator s: Fabien Maldonado, M D and Najib Rahman, DPhil MSc FRCP  
 
Statistician : Tatsuki Koyama, PhD  
 
Advisor : Pi[INVESTIGATOR_266554], MD  
 
        
Title: Navigation  endoscopy to reach indeterminate lung nodules versus  transthoracic needle aspi[INVESTIGATOR_1516], a 
randomized controlled s tudy (VERITAS)  
 
2.  Statement of compliance  
 This human subject study will comply with all applicable federal, state and local laws and regulations, including 
generally accepted standards of good clinical practice as adopted by [CONTACT_266574] (“FDA”) regulations and statutes. Participating study sites shall only allow individuals who are appropriately trained and 
qualified to assist in the conduct of the study.  
  
3. Purpose  of the study  
 
3.[ADDRESS_324477] cancer combined, 
representing approximately 160,000 deaths every year.1 In 2011, the National Lung Screening Trial (NLST) 
demonstrated a 20% relative reduction in lung cancer mortality with annual low -dose computed tomography 
(LDCT).[ADDRESS_324478] computed tomography (CT) in the 
US, translating to around 4,[ADDRESS_324479],  approximately 40% of individuals 
randomized to LD CT screening had one or more nodules identified during the study period, the vast majority of 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324480] probability of malignancy as 
determined by [CONTACT_266575]. Low -probability (< 10% chance of 
malignancy) are followed radiologically with serial CT, while high pre -test probability nodules (> 70% chance 
of malignancy) are typi[INVESTIGATOR_266555] , although tissue confirmation is often necessary even for these 
nodules.[ADDRESS_324481] -guided biopsy is associated with a general yield estimated at 90%, 
although studies focusing on nodules < 1.[ADDRESS_324482] reported yields between 70% and 80%.6-8There has not 
been randomized controlled studies comparing CT -guided biopsy to other approaches.  The technique is 
associated with substantial complications: in a population -based study, the rate of pneumothorax  was 15% with 
need for chest tube management in 7%, and the risk of hemorrhage was 1%.9  Conversely, bronchoscopic 
biopsy is safer with reported 1.6% pneumothorax, with a need for chest tube management in 0.7%,  and a 0.5% 
hemorrhage risks , but best estimates of yield using conventional navigation techniques approach 75 %, with 
rates below 50% in registry data.10-[ADDRESS_324483] images obtained at lung volumes substantially 
different than those achieved during deep sedation or general anesthesia  required during bronchoscopy.  The 
recently introduced FDA-approved enhanced fluoroscopy imaging device, F -Nav (SuperDimension, Medtronic, 
Minneapolis, Minnesota, [LOCATION_003] ), allows visualization of fluoroscopi[INVESTIGATOR_897]- invisible nodules, re -registration and 
adjustment of the target . Using this more “real time” technique, the diagnostic yield approac hes 85% in 
retrospective data from Vanderbilt University Medical center, Nashville, TN. In addition, endobronchial ultrasound biopsies of mediastinal lymph nodes are diagnostic in 13% of patient without CT or PET scan 
abnormalities, which emphasizes the importance of  bronchoscopy.
[ADDRESS_324484] -guided biopsy: (1) avoidance of pot entially life -threatening complications 
associated with CT -guided biopsies, (2) performance of complete mediastinal staging via endobronchial 
ultrasound when malignancy is confirmed, in a single procedure under a single sedation / anesthetic  session  and 
(3) potential biopsy of multiple indeterminate lung nodules in the same procedure. This has the potential to 
significantly decreas e mortality, morbidity and healthcare costs, and if proven, to be a robust diagnostic 
methodology, to become the standard of care for thousands of patients per year .  
 
3.2 Aims  and O bjectives  
In this study, we propose to study in a 1:1 randomized controlled trial the diagnostic accuracy  of 
navigation bronchoscopy (NB)  with F-Nav (SuperDimension iLogic 7. 2 ENB platform and later  
(SuperDimension, Medtronic, Minneapolis, Minnesota, [LOCATION_003]) ) using a non -inferiority study design (primary 
endpoint)  versus the current clinical standard of care: CT -guided biopsy . We will in addition compare: 
complications rate including rate of p neumothorax and clinically significant bleeding, need for hospi[INVESTIGATOR_266556] [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
10 of 38 
 after procedure, time to procedure, duration of the procedure, need for additional nodule biopsy, need for 
additional procedure for staging, radiation exposure from fluoroscopy and C T, and need for F -Nav during 
navigation bronchoscopy (secondary endpoints).  Follow up has been chosen to be pragmatically deliverable 
while allowing full assessment of key outcomes, including false negatives to provide a robust, clinically 
meaningful trial result.  
4. Study Design   
 
4.1 General Study Design  
This is a randomized  1:[ADDRESS_324485] importa nt outcome (diagnostic 
accuracy ) in the presence of a technology which is likely to reduce significant current complications / adverse 
events , and allow in the same procedure mediastinal staging and, potentially, additional bronchoscopic 
interventions (such as airway inspection, biopsy of additional nodules) . 
 
4.2 Patient Inclusion and E xclusion Criteria 
Inclusion criteria:  
 
1. Patient  is ≥ 18 years of age at time of sign ing informed consent . 
 
2. Patient is r eferred for biopsy of a single indeterminate pulmonary nodule , with the following 
characteristics regarding size, location, accessibility, and probability of malignancy:    
a)  Intermediate or high pre -test probability of malignancy as defined by a pre -test probability  of 
malignancy between 10% and 100% , using a validated clinical prediction model, which is 
either:   
i. The Brock model14 if no PET scan data are available, or   
ii. The Herder model15 if PET -CT data are available.    
b)  Size between 10 and 30 mm  (long diameter) .  
c) Location peripheral , here defined as occupying the middle or outer third lung zones .  
d) A ccessible via navigation bronchoscopy and also accessible via CT -guided biopsy (i.e. the 
nodule is clinically suited to equal access by [CONTACT_266570]) , as confirmed by [CONTACT_266576] (see S ection 4. 5).   
Note: Prior to randomization, the main purpose of this  study-provided 
central review is to establish panel agreement with local expertise offered by [CONTACT_266577], that local management of a consented  
candidate patient at the site can be achieved by [CONTACT_266578] [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324486] -guided biopsy 
(with either procedure able to be performed at the local institution) . 
 
Exclusion criteria:  
 
1. Patients with proximal nodules, as defined by [CONTACT_266579] 1/3 of the lung by 
[CONTACT_266580] (described below)  will not be eligible for the study . 
 
2. Patients with multiple nodules requiring biopsy (patients may hav e other nodules not considered for 
biopsy).  
3. Radiologically abnormal mediastinal or hilar lymph nodes requiring endobronchial ultrasound. 
 
4. Patients for whom stereotactic body radiation therapy is planned even if biopsies show no evidence of malignancy . 
 
5. Patients with contraindication to biopsy  or deep sedation/general anesthesia. 
 
6. Patients unable or unwilling to comply with study follow -up schedule . 
 
7. Patients previously randomized to  the study. 
 
8. Patients unable to provide documented informed consent . 
 
9. Patient s who are nursing or pregnant as verified by a n optional  standard of care pregnancy test . (Testing 
required only if deemed clinically necessary by [CONTACT_102]’s study physician.)  
 
4.3 Withdrawal of P atients  
The reasons for study exit of all enrolled patients will be documented on the applicable case report form 
electronic case report form (eCRF). In the event patient withdraws consent during the study, the date of 
withdrawal will be documented. If the study investigator voluntarily removes a subject from further study 
participation, supporting documentation must be in place for the rationale and date of removal. Every attempt 
will be made to contact [CONTACT_266581]- compliant: subjects will be considered lost to follow -up once the 
following steps have been taken:   
• Two phone calls should be made to the patient. Each attempt should be clearly documented in the source documents and the response or lack thereof should be captured.   
• If there is no response to the phone calls, then certified letter should be sent. A copy of the letter will be 
kept on record.   • After a period of two weeks after  the aforementioned interventions, the patient will be considered lost to 
follow- up. Study exit form will be completed. 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324487] of care setting will be evaluated by a lung nodule expert at the study 
site for the presence of a single 10- 30mm (longest diameter) indeterminate peripheral lung nodule with a pre-
test probability of malignancy between 10% and 100 %. Consented patients will subsequently receive additional 
review by [CONTACT_266582][INVESTIGATOR_266557], in order to verify the patient’s single indeterminate 
peripheral lung nodule  is suitable for both navigation bronchoscopy and CT -guided biopsy.  
 
4.[ADDRESS_324488]-guided biopsy. Neither expert will be aware of the other ’s decision. The panel is required to give a view if 
either of these techniques is technically feasible (and not which i s “better”) , with the interventional 
pulmonologist assessing the feasibility of navigation bronchoscopy and the interventional radiologist assessing that of CT -guided biopsy. Each participating institution receives an institution -wide account of the 
LungCloud™ platform. The LungCloud™ is provided by [CONTACT_266583] , a spin -off of Vanderbilt 
University. The LungCloud™ is a health IT clinically approved system for the collection of complete data sets 
in the clinical flow, including but not limited to clinical outcome, radiology notes and scans. The LungCloud™ is set up  as a network of accounts that can be interconnected around a clinical study. The managing institution 
creates a Clinical Trial inside the LungCloud ™ and ties it to each of the institutions. Each institution is then 
able to collect and share data for the clinical study. Data is collected in the clinical flow and from PACS and 
stays at all time in the LungCloud ™ instance of the institution owning the data. 
 
 Image data is encrypted and sent to the institution’s LungCloud™. Automatic uploading of images is ac hieved 
through what is referred to as the LungDrive. This is a process that runs on the end user’s machine and works in a way similar to Box or Dropbox, i.e., any new image volume placed in a specific folder is automatically 
encrypted and uploaded to the account repository.  The non- imaging data can be entered into the system and 
associated with the imaging data through web- based forms customized to the end users. Images are 
reconstructed in 3D and can be reviewed in any view (sagittal, coronal or axial). T he system offers a series of 
web-based user interfaces that permit inspecting and visualizing both imaging and non- imaging data.  
 
The LungCloud™ allows each site’s clinical study coordinator to manage patients that have to be added to the 
clinical study. I nformed consent can be electronically acquired or added manually in the system. After informed 
consent has been obtained, the patient’s de -identified data will be shared with the study primary site.  
 As part of the study, the subject’s chest CT will be dis played in the clinical study review web -portal for analysis 
by [CONTACT_266584]  (1) an interventional pulmonologist expert in navigation 
bronchoscopy and (2) an interventional radiologist expert in CT -guided biopsy. The lung nodule will be 
assessed for its location in the proximal, middle or oute r third of the lung  by [CONTACT_266585] a validated software analysis . Nodules accessible by [CONTACT_266586], conventional 
bronchoscopy or linear EBUS will be excluded. Nodules located in the middle or distal third will be included. If 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324489] -guided biopsy approach, the patient will be 
randomized.  
 
This assessment involving central review by [CONTACT_266587] 3 business 
days  after informed consent is obtained . Subsequent r andomization of eligible patients is anticipated in 
conjunction with confirmation of enrollment (as outlined below in Section 5), with init iation of navigation 
bronchoscopy or CT -guided biopsy to occur within 3 weeks ( 30 calendar days) after a site is notified of 
randomization. In the event that a CT scan cannot be uploaded to LungCloud™ expeditiously enough for 
adjudication to occur within the mandatory [ADDRESS_324490] slices uploaded to CRF 2 in the study REDCap database.  
 
Exclusion criteria for accessibility via navigation bronchoscopy:  
1. Nodules with an airway greater/equal to  [ADDRESS_324491] -guided biopsy:  
1. All nodules for which a fissure would have to be crossed  
2. All nodules for which a large bulla would have to be crossed  
3. All nodules located in areas deemed unreachable by [CONTACT_266588] a nodule falls into the outer 1/3, middle 1/3 or proximal 1/3 of the  lung parenchyma , proprietary 
software with be utilized to map  zones of the lung  as previously described.16 “CT Pulmo 3D” workflow using 
OsiriX which automatically analyzes the lung parenchyma and defines the contours of both lungs. If a nodule is within the outer 2/3 of the lung parenchyma or the nodule touches the border of the outer 2/3 of the lung 
parenchyma the nodule will be considered candidate for study. Each site will be provided with the zone of the 
nodule (outer, middle or inner 1/3) and an image of the lung zones and nodule prior to the procedure.  The figure 
below depi[INVESTIGATOR_266558] 1/[ADDRESS_324492] Pulmo 3D.  
 
 
 

   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
14 of 38 
 4.6 Interv ention  Arm : Bronchoscopy Pathway  
The intervention arm will consist of electromagnetic (EMN) navigation bronchoscopy using the Medtronic 
SuperDimension platform with F -Nav. Patient s’ available DICOM CT images will be uploaded into the 
planning software. CTs obtained more than [ADDRESS_324493] not meeting minimal 
technical requirements for optimal roadmap planning (adequate CT reconstructions and slice thickness of 
1.5mm or less) will be repeated before the procedure. Bronchoscopy will be performed by [CONTACT_266589] (as defined by [CONTACT_726] [ADDRESS_324494] 25 of these performed with F -Nav). Procedures will be performed under general 
anesthesia with neuromuscular blockade (to facilitate breath holds required for FNAV image acquisition) in a 
dedicated bronchoscopy suite or operating room . Bronchoscopy will be performed as previously described with 
confirmation by [CONTACT_266590].17 Suggested intraprocedural flow is detailed in the figure in section #14. 
Radial ultrasound will be used for confirmation only, and not as a navigational tool (i.e. catheters not aligned with the registered target will be considered non-diagnostic). Biopsies will be obtained using a any -gauge 
needle, with at least [ADDRESS_324495] to exclude 
pneumothorax, and , if indicated , ultrasound and/or formal  chest radiograph as per standard of care. The 
procedure will be deemed non- diagnostic if the proceduralist is unable to reach the nodule or if a complication 
occurs and therefore no biopsy is obtained.  
 
4.7 Comparison: CT -guided Biopsy Pathway  
The control arm of the study will consist of CT -guided biopsy, which will be performed by [CONTACT_266591]/or fine needle aspi[INVESTIGATOR_1516] (as defined by [CONTACT_726] 
[ADDRESS_324496] two years  as a department ). Procedures will be performed in a dedicated 
interventional CT scanner with multi- slice capabilities.  Patient analgesia with local anesthesia and moderate 
conscious sedation will be used. Biopsy number, core biopsy vs. fine needle aspi[INVESTIGATOR_1516], use of coa xial needles, 
and use of rapid on- site cytologic examination will be at the discretion of the proceduralist per local institutional 
preferences. Procedures will be followed by [CONTACT_266592]/or chest radiograph to exclude pneumothorax 
if required per local standard of care. The procedure will be deemed non- diagnostic if the proceduralist is 
unable to reach the nodule or if a complication occurs and therefore no biopsy is obtained.  
 
1. Patients not eligible for general deep sedation and general anesthesia and therefore not eligible for 
bronchoscopy, but potentially eligible for CT -guided biopsy, will be excluded from the study but 
recorded as such in the CONSORT diagram.  
 
2. Patients randomized who fail to present for their assigned intervention will be considered screen -
failure  
 
3. Patients randomized who present for their assigned intervention but do not undergo the 
procedure for reasons other than for contraindications to the procedure (per institutional policy) 
will be analyzed  as non -diagnostic procedure , and otherwise considered  screen -failure. The cause 
for cancellation will be recorded in the case report form.  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
15 of 38 
  
See Procedural Flow Chart (Section 1 4).  
  
 
4.[ADDRESS_324497]. 
Definitive diagnoses are pre- defined as any of the following:   
• Malignancy  on histological samples , OR 
• Biopsies with abnormal tissu e (excluding normal or absence of lung parenchyma) that are followed by a 
surgical lung biopsy yielding the same histological diagnosis , OR  
• Specific benign histopathologic finding which accounts for the presence of a lung nodule (specifically including organizing pneumonia, frank purulence, granulomatous inflammation, or other specific benign 
finding)  AND  
• Absence of malignancy (true negative) over [ADDRESS_324498] follow -up, defined as:  
o the nodule markedly regresses or resolves on follow -up imagi ng, OR  
o a persistent nodule has not been diagnosed as malignant, AND  
o there are no plans for repeat invasive diagnostic procedures through 12 months follow -up.  
 
Biopsies with normal  or absence of  lung parenchyma , atypia or mild inflammation  will be considered non-
diagnostic. All diagnoses (from both arms) will be determined by a blinded, independent, expert lung 
pathologist (i.e. blind to the biopsy technique) and all non- diagnostic biopsy specimens will be reviewed by [CONTACT_266593].  
Linear EBUS for lymph node interrogation and staging will be performed in the same procedure after  the 
navigation bronchoscopy for staging purposes as per standard of care . 
  
Secondary endpoints  
• Rate of pneumothorax  
• Rate of pneumothorax requiring chest tube placement  
• Clinically significant bleeding  (defined by [CONTACT_266573])   
• Need for hospi[INVESTIGATOR_266552]  
• Duration of the procedure  (from bronchoscope in to bronchoscope out for the bronchoscopy arm and 
from first needle in to last needle out for CT -guided biopsy)  
• Procedural factors associated with improved yield (type of biopsy, number of biopsies , use of radial 
ultrasound, presence of a bronchus sign, biopsy site)  
• Need for additional nodule biopsy 
• Need for additional procedure for staging 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
16 of 38 
 • Radiation exposure from fluoroscopy- guided bronchoscopy and CT  for C T-guided biopsy 
• Need for F -Nav during navigation bronchoscopy 
• Adequacy of specimens collected for molecular testing when needed . 
• Diagnostic yield, defined as the rate at which histopathology is obtained which explains the presence of 
a nodule (according to definitions set forth for the primary endpoint) and  permits post -biopsy clinical 
decision -making without need for immediate additional diagnostic procedures.  
• Rate at which the biopsy procedure yields a confident clinical diagnosis (including any added yield from 
endobronchial ultrasound- guided mediastinal and/or hilar lymph node biopsies or microbiologic studies 
which yield an explanation for a nodule despi[INVESTIGATOR_266553]- diagnostic biopsy specimens).  
 
4.9 Centralized Pathology Review  (Core Lab Confirmation)  
An independent expert lung pathologist will review all non- diagnostic and benign cases. In case of 
disagreement with the initial pathology review, a third expert lung pathologist will adjudicate the case.  
 
In all cases, management after intervention -biopsy will be as per standard of care . i.e. patients will be managed 
according to a participating site’s conventional clinical guidelines. For example, patients after a negative biopsy 
may (1) cross -over to another minimally invasive biopsy, (2) be followed with serial chest CTs or (3) undergo 
surgery. These subsequent procedures will be part of normal patient care and only be regarded as follow -up data 
for the purpose of this study (i.e. non- randomized bronchoscopi[INVESTIGATOR_266559] -guided biopsies will not affect the 
diagnostic yield for the purpose of this study).  
 
Patients will be followed for up to [ADDRESS_324499] i f clinically indicated (non -
malignant pathology without resolution on interval imaging), with suggested scanning cadence at 3 months, 6 
months, and 12 months .  
 
4.10 Study Flow  
See Procedur al Flow Chart (Section 1 4), Screening F low C hart (Section 1 5) and Study A ssessment Table 
(Section 1 6). 
5. Enrollment Procedures  
 The Vanderbilt -Ingram Cancer Center (VICC) Coordinating Center will coordinate enrollment in the study.  
 Prior to registration, a copy of the IRB approval at the site will be kept on file at the Vanderbi lt-Ingram Cancer 
Center (VICC) Coordinating Center. Eligible participants will be entered on study centrally in OnCore at the VICC Coordinating Center.  
 All patients MUST be registered with the Vanderbilt -Ingram Cancer Center (VICC) prior to the start of 
study procedures such as tissue acquisition.  Registration can only be conducted during the business 
hours of 8AM – 5PM Central Time, Monday through Friday.   
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
17 of 38 
 Enrollment Process:  
Potential patients will be screened using the REDCap  VERITAS e -Eligibility tool. Eligible patients will 
be approached by [CONTACT_266594]. Patients who agree to participate will provide signed research informed consent. This can be accomplished using a printed paper consent 
form which is then scanned and uploaded to VERITAS e -Eligibility upon completion, or electronically 
via the e- consent module embedded within VERITAS e -Eligibility, in which patients may sign research 
informed consent electronically (either in clinic or after the e -consent form is emailed to them following 
full informed consent discussion from key study personnel over the phone).  Once signed research 
informed consent has been obtained, a record for the subject is created in the REDCap VERITAS 
database.  Central adjudication are performed within three business days as described in section 4.5, with 
determinations entered into the VERITAS database. Once central adjudication is complete, the subject’s 
e-eligibility CRF part 2 is completed indicating whether they are eligible for ra ndomization after central 
adjudication. Eligible patients are then randomized via a randomization module embedded within the VERITAS database.  
 
Note :   
Upon satisfactory review of eligibility documents submitted, the Coordinating Center will approve enroll ment 
and issue a subject ID number if one was not issued at screening.  Once registration/enrollment confirmation from Coordinating Center is received, proceed with protocol procedures.  
Please contact [CONTACT_266595].  You can also reach out to 
your assigned CRA once the study is activated.  
The VICC Coordinating Center will assign Subject ID numbers to all patients whose eligibility has been confirmed.  Only patients deemed eligible will be registered to the study.  Sequence/study ID numbers will not 
be re- used if a patient screen fails.  Following registration, eligible participants should begin the study 
consistent with the protocol no later than 28 days after registration/enrollment by [CONTACT_266596].   
Following registration, eligible participants should initiate navigation bronchoscopy or CT -guided biopsy no 
later than 30 business days  after the site is notified of randomization by [CONTACT_266597]. If a 
participant does not receive the procedure following randomization within the allowed time period, the patient may be re- consented or participant ’s registration on the study will be canceled. The Study Contact [CONTACT_266598].   
The purpose of this [ADDRESS_324500] been utilized in clinical practice outside of this trial. For example, if biopsy 
procedure #1 cannot be performed for 8 weeks due to local factors (equipment failure, perhaps), but biopsy 
procedure #2 could be performed within two weeks, the 30- day window protects this patient from a potentially 
harmful delay in a malignant diagnosis by [CONTACT_266599] #[ADDRESS_324501] be scheduled outside the 30-day 
window but 1) the alternative procedure cannot be performed meaningfully sooner and 2) the delay in biopsy is 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324502] any eligibility criteria, the patient may remain in the trial  (an example in which point #2 
might be invoked: a patient with a [ADDRESS_324503] grown to exceed 30 mm diameter and therefore no longer be eligible for the 
trial). This determination must be agreed upon by [CONTACT_266600] [INVESTIGATOR_266560] (Maldonado) and will be 
documented in the "notes" field at the end of REDCap CRF #1.  
 As is generally accepted, standard of care procedures performed prior to consent, but within the protocol 
defined screening window for each assessment, can be used for study purposes. All research- only procedures 
must be performed after patient consent.   
 
Subjects who provide informed consent, but are determined to be ineligible prior to initiation  of navigation 
bronchoscopy or CT -guided biopsy will be considered screen failures and the reason for screen failure will be 
documented. Subjects who fail to present to their assigned procedure after randomization will be considered 
screen failures as well . Subjects who present to their assigned procedure but do not undergo the procedure for 
reasons other than safety will be analyzed on an intention- to-treat basis (see above S ection 4. 7 for details).  
 
6. Methodology   
 
6.[ADDRESS_324504] -guided biopsy performed by [CONTACT_147878]. Eligible 
patients will be randomized on a 1:1 basis and the randomization will be stratified  by [CONTACT_266601]:   
1. Location in the middle or outer third of the lung  
2. Pre-test probability of malignancy ( 50% or less VS 51% or more)  
 Within each stratum , block sizes of [ADDRESS_324505] -guided biopsy is 90%. The non- inferiority margin  is set 
at 10 percentage points, and one -sided type I error rate is set at 5%. Thus, if the true diagnostic accuracy  for 
navigation bronchoscopy is lower than 80%, we will have 5% probability (type I error rate) to incorrectly 
conclude noninferiority. With  this parameter setting a sample size of 112 per group will give approximately 
80% power if the true diagnostic accuracies are 90% for both arms. Considering an attrition rate of 15%, the 
sample size is  129 per group (258  total). Large volume centers could  be expected to enroll [ADDRESS_324506] 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
19 of 38 
 biopsy which is in excess of 10%, and after polling a number of clinicians who are involved in the diagnostic 
workup of patients with lung nodules, where this margin was considered reasonable .  
 
6.2 Analysis plan  
 
Analytic populations  
The analysis set will be the per -protocol (PP) population, which yields more conservative estimates for the 
noninferiority objective than the intention- to-treat (ITT) population. The ITT analysis will include every 
randomized subject assigning a treatment failure for those who drops out without the final data. The ITT analysis will be a secondary, sensitivity analysis.  
 Prior distribution  
The probability of successful diagnostic accuracy  for each treatment arm will be modeled with a Beta- Binomial 
distribut ion. A non- informative prior Beta (1,1) will be used for both treatment arms.  
 Interim analysis  
No interim analysis is planned for this trial. Interim analyses typi[INVESTIGATOR_266561] -way through  a trial. However, the primary outcome of diagnostic accuracy 
requires up to [ADDRESS_324507] of care options for the tissue sampling of lung 
nodules, complications of these procedures themselves are not considered risks unique to this research. The 
primary risk to participation in this research involves patient privacy and confidentiality, any breach of which 
will be reported to the PI [INVESTIGATOR_266562], which does not require interim analysis.  
  
Final analysis  
The final analysis will be conducted when data from all randomized patients are available (n=112 per group). The conclusion will be based on the final posterior distributions  (n=112 each). We will conclude noninferiority 
of NB compared to CT if the estimated probability  of inferiority is  less than 5%. We will conclude superiority 
of NB if the estimated probability that NB is better than CT is higher than 95%.  
 The median estim ate and 95% credible interval will be given for the diagnostic accuracy  for NB and for CT, as 
well as their difference.  Additionally, we will estimate and report the probability that NB is non -inferior to CT 
and NB is superior to CT. These probabilities can be estimated using the posterior distributions of diagnostic 
accuracies . 
 Subgroup analysis:  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324508] or pulmonologists, etc… The full list of subgroup pre -hoc analyses will be defined in the statistical 
analysis plan which will be completed and signed off by t he trial steering committee prior to final patient entry 
and prior to any prior full analysis of the data. To allow for comparison of diagnostic  accuracy and yield 
differences across subgroups (e.g., middle vs outer third), logistic regression models with interaction with 
treatment group will be fit.  
 
Operating characteristics  
With the Bayesian paradigm, there is no type I error rate. We conducted a simulation study to determine appropriate threshold for noninferiority conclusion and superiority conclusion at the final analysis. The 
operating characteristics of the proposed design under various scenarios for the true unknown parameter 
distributions were evaluated and shown in the below table . In this simulation study, we first postulated the true 
distributio n of the diagnostic accuracy  using a Beta distribution, which gives the specific mean and standard 
deviation. For example, Beta(141, 35) is used to represent a distribution with mean 0.[ADDRESS_324509] deviation 
(sd) 0.03. We used 0.60, 0.70, 0.80, and 0.[ADDRESS_324510] deviations yielded similar results, we only present the results for sd=0.03. The simulation size is 10,000 and the available decision in the simulation is: conclude non- inferiori ty at final analysis (> - 10%).  The 
following table shows its  probability under various scenarios.  
Design characteristics with final 10% (0.95)  
     Final analysis  
True CT  
Mean  True 
NB 
Mean  True State  Difference    NB is  
non-
inferior  NB is  
superior  
0.7 0.6 Inferiority  -0.1   5.3 -- 
0.8 0.7 Inferiority  -0.1   4.7 -- 
0.9 0.8 Inferiority  -0.1   5.4 -- 
0.8 0.6 Inferiority  -0.2   -- -- 
0.9 0.7 Inferiority  -0.2   -- -- 
0.7 0.7 Non-inferiority  0.0   44.9 4.9 
0.8 0.8 Non-inferiority  0.0   54.2 4.9 
0.9 0.9 Non-inferiority  0.0   74.4 4.7 
0.6 0.7 Superiority  0.1   47.0 46.5 
0.7 0.8 Superiority  0.1   43.7 53.0 
0.8 0.9 Superiority  0.1   31.7 67.8 
0.6 0.8 Superiority  0.2   4.8 95.1 
0.7 0.9 Superiority  0.2   1.3 98.7 
Probabilities less than 1% are not shown.  
  
 
 
 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
21 of 38 
 6.3 Variables Recorded  
• Past medical history  
• Demographic data  
• Smoking history  
• Occupational history 
• Current medications  
• Laboratory data (complete blood count, electrolytes, creatinine, coagulation profile if available , results 
of fungal serologies if available ) 
• Chest CT characteristics:  
o Location of the nodule (lobe and segment)  
o Nodule size (longest axis)  
o Distance to the nearest visible bronchus on either CT plane (axial, coronal or sagittal)  
o Bronchus sign (airway aligned with nodule)  
o Distance to the nearest parietal pleura  
• PET scan characteristics (FDG uptake (SUV))  
• Procedural characteristics:  
o Duration of procedure  
o Number and type of biopsies  
o Use of FluoroN av, and divergence in mm if used 
o Radiation exposure  
o Complications (pneumothorax, bleeding, others)  
• Time to procedure (delay between decision to biopsy and procedure)  
• Time from identification of nodule to treatment for malignant nodules  
• Need for another biopsy modality  
• Need for an additional staging procedure  
• Follow- up data . 
 
 
7. Safety  Reporting of Adverse Events  
 
7.1 Grading  
Adverse events will be graded according to the NCI’s Common Terminology Criteria for Adverse Events (NCI 
CTCAE), Version 5.0, dated November 27, 2017, currently locatable via the following URL:  
<https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x
11.pdf  >. 
 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
22 of 38 
 If events are not listed in the CTCAE, severity may be designated as mild, moderate, severe, life- threatening, or 
fatal which respectively correspond to Grades 1, 2, 3, 4, and 5 on the NCI CTCAE, with the following 
definitions:  
• Mild:  Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated;   
• Moderate:  Minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental 
activities of daily living (ADL) such as preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc;   
• Severe:  Medically significant but not immediately life -threatening; hospi[INVESTIGATOR_24599]; disabling; limiting self care ADL such as bathing, dressing and undressing, feeding self, using the toilet, taking medications;  
• Life-threatening:  Urgent intervention indicated to prevent risk of death present at the time of the event;   
• Fatal:  An event that results in the death of the patient.  
 
Information on adverse events, whether serious or not, whether reported by [CONTACT_2299], directly observed, or 
detected by [CONTACT_5292], laboratory test or other means, will be collected, recorded, followed and 
reported as described in the following sections.  
 
7.[ADDRESS_324511] of care  for management of 
indeterminate pulmonary nodules. Therefore, collection of data regarding adverse events and serious adverse 
event s will be limited in this study :  
• Any serious or non- serious adverse event related to research procedures ( i.e. the consent process, 
HIPAA compliance, etc.) will be collected.  
 
• After informed consent but prior to initiation of navigation bronchoscopy or CT -guided biopsy, serious 
and non- serious adverse events should be reported only if possibly, probably or definitely attributed by 
[CONTACT_102]’s study physician to a protocol -mandated research procedure or intervention.   
• The principal AE reporting period will be within [ADDRESS_324512] -procedure day #[ADDRESS_324513] not already risen to investigator awareness.  
 
• Any serious adverse event that occurs ≤ [ADDRESS_324514] be reported to the Coordinating Center in an expedited fashion as directed below (Reporting Procedures).     
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324515] -guided biopsy or the next phase of the patient’s treatment  or management  should NOT be recorded.  
Participants should be instructed to report any serious post -study event(s) that might reasonably be related to 
participation in this study. The investigator should notify the IRB and the Coordinating Center of any 
unanticipated death or adverse event occurring after a participant has discontinued or terminated study 
participation that may reasonably be related to the study.  
 
7.[ADDRESS_324516] of care setting . These risks, inherent in t he 
procedures themselves , include pneumothorax, bleeding, pain, or, rarely, infection. Risk  of death is estimated 
around 1/ 10,000. We do not expect that enrollment in this study  will result in an increased risk for the patient.  
 
The greatest risks from bro nchoscopy are related to sedation and maneuvering the bronchoscope into the 
patient’s airway. Accordingly, a nurse and/or a respi[INVESTIGATOR_266563]. In addition, pul se oximetry, respi[INVESTIGATOR_697], blood 
pressure, ECG, and heart rate will be continuously monitored. Patients will not be released until they are fully awake and medically stable as per standard local standard of care operations.   
 Other risks include those associated with biopsy and are the same as for standard flexible bronchoscopy: 
pneumothorax, breathing difficulty, vocal cord spasm, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, heart attack and bleeding from biopsied site. The occurr ence of these risks is extremely low. The 
measures to mitigate the risks are the same as for all bronchoscopy. To minimize the chance of bleeding, all patients will be questioned about tendency to bleed prior to bronchoscopy as per standard care. Anticoagulation 
with antiplatelet agents will be held according to guideline recommendations for that drug.  If bleeding occurs, 
patients will be treated with direct pressure, local instillation of iced saline or other bronchoscopic interventions as deemed necessary. Vocal cord spasm will be mitigated  with the use of lidocaine on the vocal cords. Patients 
with lung disease may receive bronchodilators prior to bronchoscopy at the discretion of the performing bronchoscopi[INVESTIGATOR_541]. Patients are given supplemental oxygen and their oxygen level is continuously monitored using 
pulse oximetry. If there is any sign of a worsening in status, such as elevated heart rate, low oxygen, or 
electrocardiogram (ECG) changes, the procedure will be aborted.   
 The risks associated with CT -guided biopsy include pneumothorax, breathing difficulty, infection, low blood 
oxygen, and bleeding from biopsied site. The predominant risk of this procedure is pneumothorax. The measures to mitigate the risks are the same for all biopsy procedures. To minimize the chance of bleeding, all 
patients w ill be questioned for their tendency to bleed prior to the procedure as per standard care.  
Anticoagulation with antiplatelet agents will be held according to guideline recommendations for that drug. If 
bleeding occurs, patients will be treated with direct  pressure. Patients are given supplemental oxygen and their 
oxygen level is continuously monitored using pulse oximetry. A nurse, respi[INVESTIGATOR_266564], heart rate, blood pressure, and blood oxygen during the  procedure. If there 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324517] names and protected health 
information (PHI) will be kept confidential to the extent possible and as required by [CONTACT_198990]. All records and data related to the study will be maintained in a secure protected  space, with access 
restricted to study personnel or individuals designated by [CONTACT_107878] (i) need access to the information to fulfill the terms and obligations of the Coordinating Site or the Sponsor under the Protocol and (ii) are under 
the sam e obligations as study personnel to keep the information confidential.   
 
7.5 Benefits  
There is no guarantee that the subjects will receive any benefit from this study.  
 
7.6 Definitions 
7.6.1 Adverse Event (AE)  
An adverse event is any undesirable sign, symptom or medical condition or experience that develops or worsens in severity after starting the first dose of study treatment or any procedure specified in the 
protocol, even if the event is not considered to be related to the study.  
Abnormal laboratory values or diagnostic test results constitute adverse events only if they induce clinical signs or symptoms or require treatment or further diagnostic tests.  
7.6.2 Serious Adverse Event (SAE)  
A serious adverse event is an undesirable sign, symptom or medical condition which:   
• Is fatal or life -threatening;  
• Requires or prolongs inpatient hospi[INVESTIGATOR_059];   • Results in persistent or significant disability/incapacity;  • Constitutes a congenital anomaly or birth defect; or   • Jeopardizes the participant and requires medical or surgical intervention to prevent one of the 
outcomes listed above.  
 Events not considered to be serious adverse events are hospi[INVESTIGATOR_5315]:   
• Routine treatment or monitoring of the studied indication, not associated with any deterioration in condition, or for elective procedures.   
• Elective or pre- planned treatment for a pre -existing condition that did not worsen.   
• Emergency outpatient treatment for an event not fulfilling the serious criteria outlined above and 
not resulting in inpatient admission.  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
25 of 38 
 • Respi[INVESTIGATOR_4594].  
 
7.6.3 Expectedness  
Expected : Expected adverse events are those that have been previously identified as resulting from 
administration of the agent. For the purposes of this study, an adverse event is considered expected  when 
it appears in the study protocol or current adverse event list, in applicable information describing use of 
a marketed product in the standard of care setting (e.g. product manual, investigator’s brochure, package 
insert) or  is included in the informed consent document as a potential risk.  
 
Unexpected : An adverse event is considered unexpected  when it varies in nature, intensity or frequency 
from information provided in the study protocol  or current adverse event list, in applicable information 
describing use of a marketed product in the standard of care setting (e.g. product manual, investigator’s 
brochure, package insert) or when it is not included in the informed consent document as a potential 
risk. 
 
7.6.4 Attribution  
Attributio n is the relationship between an adverse event or serious adverse event and participation in the 
study. Attribution will be assigned as follows:  
• Definite – The AE is clearly related  to study participation .  
• Probable – The AE is likely related  to study participation .  
• Possible – The AE may be related  to study participation .  
• Unlikely – The AE is doubtfully related  to study participation .  
• Unrelated – The AE is clearly NOT related  to study participation . 
 
7.[ADDRESS_324518] medical terminology/concepts when reporting AEs or SAEs, and avoid 
colloquialisms and abbreviations. If known at the time of reporting, a diagnosis should be reported 
rather than individual signs and symptoms (e.g. record only liver failure or hepatitis rather than jaundice, 
asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of repo rting, it is acceptable to 
report the information that is currently available. If a diagnosis is subsequently established, it should be reported as follow -up information.  
 All deaths that occur during the protocol -specified AE reporting period, regardless of attribution, will be 
reported to the appropriate parties. When recording a death, the event or condition that caused or contributed to the fatal outcome should be reported as the single medical concept. If the cause of death is 
unknown and cannot be ascertained at the time of reporting, report “Unexplained Death.”  
 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
26 of 38 
 A pre -existing medical condition is one that is present prior to initiation of treatment or intervention 
specified by [CONTACT_760]. Such conditions should be reported as medical and surgical history. A pre -
existing medical condition should be re -assessed throughout the trial and reported as an AE or SAE only 
if the frequency, severity, or character of the condition worsens during the study. When reporting such 
events, it is important to convey the concept that the pre- existing condition has changed by [CONTACT_188215] (e.g., “more frequent headaches”).  
 
Any AE that results in hospi[INVESTIGATOR_266565]. If a patient is  hospi[INVESTIGATOR_9615] a medical or surgical procedure as a result of an AE, 
the event responsible for the procedure, not the procedure itself, should be reported as the SAE. For example, if a patient is hospi[INVESTIGATOR_15428], record the heart condition that 
necessitated the by[CONTACT_13664].  
 Hospi[INVESTIGATOR_15429]:   
• Hospi[INVESTIGATOR_201727]-existing conditions; or  
• Hospi[INVESTIGATOR_14842]; or  
• Hospi[INVESTIGATOR_15432]. 
 
7.7.2 Serious Adverse Events  
All serious adverse events, regardless of causality to study participation , will be reported to the Principal 
Investigator [INVESTIGATOR_1238]/or the Study Coordinator at each institution, and also to the Coordinating Center.  
 
All serious adverse events must be reported to the Coordinating Center within [ADDRESS_324519] be fully completed and emailed (preferred), 
faxed, or scanned to:   
ATTN: VICC CTSR Personnel  
EMAIL: [EMAIL_5162]
  
FAX: (615) [ADDRESS_324520] also be reported within 24 hours of receipt of the information by [CONTACT_093].  
 
The Coordinating Center will disseminate information regarding serious adverse events to the 
participating sites as described in FDA guidance only in the case that the event(s) is/are unexpected, and 
is/are believed to be related (i.e., possibly, probably or definitely) to the study device/medication. The 
Coordinating Center will be responsible  for reporting of events to supporters  as appropriate (outlined 
below). 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324521] from Medtronic, Vanderbilt University Medical Center acting as the Coordinating Center 
will notify Medtronic of any serious adverse event (SAE ) that occurs during the reporting period as 
defined above in Section 7.2 . Within 2 working days after the Coordinating Center initially receives the 
safety information from the site, the Coordinating Center will report the SAE ( on the MedWatch , 
Medtronic, or Vanderbilt SAE form approved by [CONTACT_266602]) to a point of 
contact [CONTACT_266603] . Follow- up SAE reports received by [CONTACT_266604] 2 working days to Medtronic using the same procedure used for transmitting the initial 
report. 
 
 
8. Data Safety and Monitoring  
 
8.1 Data Collection  
The Vanderbilt University Office of Research  will be used as a central location for data processing and 
management. Vanderbilt University, with collaboration from a consortium of institutional partners, has developed a software toolset and workflow methodology for electronic collection and management of research 
and clinical trial data. REDCap (Research Electronic Data Capture) is a secure, web -based application that is 
flexible enough to be used for a variety of types of research. REDCap provides an intuitive user interface that streamlines project development and improves data entry through real -time validation rules (with automated 
data type and range checks).  
 
REDCap also provides easy data manipulation (with audit trails for reporting, monitoring and querying patient 
records) and an automated ex port mechanism to common statistical packages (SPSS, SAS, Stata, R/S -Plus). In 
addition to traditional data capture functionality, REDCap’s survey capabilities are a powerful tool for building and managing online surveys. The research team can create and d esign surveys in a web browser and engage 
potential respondents using a variety of notification methods. All data collection projects rely on a thorough, study- specific data dictionary, defined by [CONTACT_266605], self -documenting 
process. This iterative development and testing process results in a well -planned and individualized data 
collection strategy.  
 REDCap servers are housed in a local data center at Vanderbilt, and all web -based information transmission is 
encrypted. REDCap was developed specifically around HIPAA -Security guidelines and is recommended to 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324522].  REDCap has been 
disseminated for local use at more than 940 other academic/non- profit consortium partners in 75 countries. 
Vanderbilt leads the REDCap Consortium, which currently supports more than 99,000 projects and 128,000 
users.  
 
8.2 Data and Safety Monitoring  
The Vanderbilt -Ingram Cancer Center (VICC) oversees patient safety and data monitoring for its investigator -
initiated and NIH -NCI funded clinical trials through its Data and Safety Monitoring Committee (DSMC). The 
purpose of the DSMC is to ensure the efficient implementation and management of the VICC Data and Safety Monitoring Plan (DSMP). The Committee maintains authority to intervene in the conduct of studies as 
necessary to ensure clinical research performed at V ICC achieves the highest quality standards.  
 The VICC DSMC meets on a quarterly basis and ad hoc to discuss data and safety monitoring of clinical trials 
and to oversee the VICC DSMP. Internal audits for compliance with adverse event reporting, regulatory and 
study requirements, and data accuracy and completion are conducted according to the VICC DSMP according 
to study phase and risk. The committee reviews all serious adverse events (SAE) on Vanderbilt sponsored 
investigator- initiated studies on a quarterly basis and provides DSMC SAE review reports to the Vanderbilt 
IRB.  
 
8.[ADDRESS_324523] Keepi[INVESTIGATOR_266566] (eCRF) is required and must be completed for each included participant. The completed dataset should not be made available  in any form to third parties, except for authorized 
representatives of appropriate Health/Regulatory Authorities, without written permission from Vanderbilt.  
 
To enable evaluations and/or audits from health authorities and Vanderbilt, the site investigator agrees to keep 
records including: The identity of all participants (sufficient information to link records; e.g., hospi[INVESTIGATOR_1097]), 
all original signed informed consent forms, copi[INVESTIGATOR_129299], and detailed records of any study 
drug or device disposition. To comply with international regulations, the records should be retained by [CONTACT_266606].  
 
Queries resulting from review of the eCRFs will be generated for the site and corrections will be made by [CONTACT_185268]. This will be done on an ongoing basis.  
  
9. Regulatory Considerations  
 
9.[ADDRESS_324524] (IRB) per 
current institutional sta ndards. 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324525] then immediately inform any applicable local IRB and the sponsor -investigator (or designee).  
 The sponsor- investigator (or designee) is responsible for the coordination and development of all protocol 
amendments. Once approved by [CONTACT_456] -investigator, Vanderbilt will disseminate this information to the 
participating study sites . 
 
9.2 Informed Consent  
The investigator (or his/her designee) will explain to each participant the nature of the study, its purpose, the 
procedures involved, the expected duration, the potential risks and benefits involved and any discomfort it may 
entail. Each participant will be informed that participation in the study is voluntary, that s/he may withdraw 
from the study at any time, and that withdrawal of consent will not affect subsequent medical treatment or 
relationship with the treating physician(s) or institution.  
 The informed consent will be given by [CONTACT_3553] a standard written or in electronic form at, written in non -
technical language, which will be IRB approved. The participant should read and consider the statement before signing and dating it , and will be given a copy  of the document. No patient will enter the study or have study-
specific procedures done before his/her informed consent has been obtained.  
 
In accordance with the Health Information Portability and Accountability Act (HIPAA), the written informed 
consent document (or a separate document to be given in conjunction with the consent document) will include a 
subject authorization to release medical information to the study sponsor and supporting agencies and/or allow these bodies, a regulatory authority, or Institutional Review Board access to subjects’ medical information that 
includes all hospi[INVESTIGATOR_44227], including subjects’ medical history.  
 
9.3 Ethics and Good Clinical Practice  
This study will be carried out in compliance with the protocol and Good Clinical Practice (GCP), as described 
within:  
1. ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996.  
2. Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding 
Physicians in Biomedical Research Involving Human Subjects, Helsinki 1964, amended Tokyo 
1975, Venice 1983, Hong Kong 1989, Somerset West 1996).  
 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
30 of 38 
 The investigator agrees to adhere to the instructions and procedures described within the above and thereby [CONTACT_266607].  
 
9.4 Confidentiality  
It is the responsibility of the investigator to ensure the confidentiality of patients participating in the trial and all of their medical information is maintained. Case report forms (CRFs) and other documents submitted to 
regulatory authorities must not contain the name [CONTACT_4007] a trial patient. All patients in the trial will be identified by a 
unique identifier which will be used on all CRFs and any other material submitted to regulatory authorities. All 
case report forms and any identifying information must be kept in a secure location with access limited to the study staff directly assisting  with the trial.  
 
9.5 Payment and Remuneration  
Subjects will not be paid to participate in the study.  
 
9.6 Costs  
There will be no additional costs to subjects for participating in this study. Subjects and/or their insurance companies will be responsible for all care provided as part of the procedure as this service is part of the standard 
of care they would receive f or their condition.   
 
9.7  Study Termination  
The sponsor -investigator reserves the right to terminate the study at any site and at any time. Reasons for study 
termination may include, but are not limited to, the following:  
 
• Investigator non- compliance with th e protocol, GCP or regulatory requirements.  
• Insufficient enrollment.  
• Safety concerns.  
• Decision by [CONTACT_266608], development or manufacture of 
protocol- indicated treatment  or device . 
• A request to discontinue the study by [CONTACT_165956] a recognized regulatory authority.  
  
10. Study Coordination  
 
10.1 Trial Compliance  
This is an investigator -initiated study. The Principal Investigator, Fabien Maldonado, M.D. (who may also be 
referred to as the Sponsor -Investigator), is conducting the study and acting as the sponsor. Therefore, the legal 
and ethical obligations of the Principal Investigator [INVESTIGATOR_91779] a sponsor and those of a principal 
investigator. 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324526]/Independent Ethics Committee 
(IRB/IEC) at participating institutions . Amendments should not be implemented until all necessary approvals 
have been obtained, except when necessary to eliminate an immediate hazard to study subjects.  
 
10.[ADDRESS_324527] to ethics, protocol adherence, integrity, validity of the data 
recorded on the CRFs, and adherence to regulations regarding Good Clinical Practice (GCP) and the prot ection 
of human subjects.  
 
In accordance with applicable regulations, GCP, and Coordinating Center procedures, sites will be contact[CONTACT_266609], study requirements, and their responsibilities 
to satisfy regulatory, ethical, and Coordinating Center requirements.  
During the course of the study, the Coordinating Center will routinely monitor sites for protocol compliance, compare CRFs with original source documents from individual subjects, assess drug accountability, and ensure 
that the study is being conducted according to the pertinent regulatory requirements. The review of subject 
medical records will be performed in a manner to ensure that subject confidentiality is maintained. Monitoring 
visits  will primarily be conducted remotely, and sites are required to provide the appropriate source 
documentation in order to allow for proper oversight per GCP. Investigators must agree to cooperate with the Coordinating Center to ensure that any problems det ected are resolved.  
 
10.[ADDRESS_324528] the appropriate source documentation. This will be 
conducted remotely, with the possibility of on- site verification periodically. Discrepancies in the data will be 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
32 of 38 
 brought to the attention of the investigator and/or the investigator’s s taff. Any necessary corrections will be 
made directly to the eCRFs or via queries by [CONTACT_1755]/or the investigator’s staff.  
10.6 Study Documentation  
Each participating site is responsible for submitting copi[INVESTIGATOR_266567]. The required documents include but are not limited to the following: IRB approvals (i.e., 
protocol, consent form, amendments, patient brochures, recruitment material, etc.), each participant’s informed 
consent, enrollment form,  eligibility checklist, summary of unanticipated problems or protocol deviations, and 
documentation of expertise of the investigators. The Coordinating Center will provide each participating site with a comprehensive list of the necessary documents. Specif ied members at each participating site will submit 
all pertinent regulatory documents to the Coordinating Center, for storage in a secure location. It is the responsibility of the participating sites to maintain copi[INVESTIGATOR_266568].  
 
10.7 Closure of the Study  
The Coordinating Center reserves the right to discontinue a site at any time during the study for medical or administrative reasons such as:   
• Unsatisfactory enrollment;  
• GCP noncompliance;  
• Inaccurate or incomplete  data collection;  
• Falsification of records;  
• Failure to adhere to the study protocol.  
 
10.8 Records Retention  
FDA regulations (21  CFR §312.62[c]) require that records and documents pertaining to the conduct of this 
study, including CRFs, consent forms, laborator y test results  and physical exam, imaging and medical 
procedure records, must be retained by [CONTACT_25733]’s Principal Investigator [INVESTIGATOR_8178] [ADDRESS_324529] be approved by [CONTACT_456] -
investigator and will be circulated to applicable participating sites/investigators prior to submission for publication or presentation. A publication plan consistent with th e international Committee of Medical Journal 
Editors (ICMJE) will be created prior to analysis ad publication of any data. All data will be ma de available to 
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
[ADDRESS_324530] -hoc analyses, or single -center experiences will not 
precede the primary multicenter publication. Publication of results will be determined by [CONTACT_473], 
without limitations f rom the funder . Input (non- binding) will be obtained from the funder who will be given 
access to the data after closure of the study. All authors are expected to disclose financial or affiliations that 
could be considered conflicts of interest per journal or medical society requirements.  
 
  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
34 of 38 
 12. References  
 
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.  
2. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung -cancer mortality with low -dose 
computed tomographic screening. N Engl J Med. 2011;365(5):395-409.  
3. Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Ame rican journal of respi[INVESTIGATOR_102814]. 2015;191(1):19-33.  
4. Gould MK, Tang T, Liu IL, et al. Recent Trends in the Identification of Incidental Pulmonary Nodules. American journal of 
respi[INVESTIGATOR_4447]. 2015;192(10):1208-1214.  
5. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence -based clinical practice guidelines (2nd edition). Chest. 2007;132([ADDRESS_324531]):108S -130S.  
6. Chang CY, Tzao C, Lee SC,  et al. Incremental value of integrated FDG -PET/CT in evaluating indeterminate solitary 
pulmonary nodule for malignancy. Mol Imaging Biol. 2010;12(2):204-209.  
7. Kothary N, Lock L, Sze DY, Hofmann LV. Computed tomography- guided percutaneous needle biopsy of pulmonary 
nodules: impact of nodule size on diagnostic accuracy. Clin Lung Cancer. 2009;10(5):360- 363. 
8. Ng YL, Patsios D, Roberts H, et al. CT -guided percutaneous fine -needle aspi[INVESTIGATOR_266569] 
10 mm or less. Clin Radiol. 2008;63(3):272-277.  
9. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung 
biopsy of a pulmonary nodule: an analysis of discharge records. Annals of internal medicine. 2011;155(3):137-144.  
10. Ost DE, Ernst A, Lei X, et al. Diagnostic Yield and Complications of Bronchoscopy for Peripheral Lung Lesions. Results of 
the AQuIRE Registry. Am J Respir Crit Care Med. 2016;193(1):68-77.  
11. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta -analysis of guided bronchoscopy for the evaluation of the pulmonary 
nodule. Chest. 2012;142(2):385-393.  
12. Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One -
Year Results of the Prospective, Multicente r NAVIGATE Study. J Thorac Oncol. 2018.  
13. El-Osta H, Jani P, Mansour A, Rascoe P, Jafri S. Endobronchial Ultrasound for Nodal Staging of Patients with Non-Small -
Cell Lung Cancer with Radiologically Normal Mediastinum. A Meta -Analysis. Ann Am Thorac Soc. 2018;15(7):864-874.  
14. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. 
The New England journal of medicine. 2013;369(10):910-919.  
15. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and 
added value of 18F -fluorodeoxyglucose positron emission tomography. Chest. 2005;128(4):2490-2496.  
16. Thiboutot J, Lee HJ, Silvestri GA, et al. Study Design and Rationale: A Multicenter, Prospective Trial of Electromagnetic Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules 
(ALL IN ONE Trial). Contemporary clinical trials. 2018;71:88-95.  
17. Khandhar SJ, Bowling MR, Flandes J, et al. Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 
subjects: first results of the prospective, multicenter NAVIGATE study. BMC Pulm Med. 2017;17(1):59.  
 
  
   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
35 of 38 
 13. CONSORT Flow Diagram  
 

   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
36 of 38 
 14. Procedural Flow Chart  
 

   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
37 of 38 
 15. Screening Flow Chart  
 
  

   
 
THO [ZIP_CODE]: VERITAS study  
Version 29MARCH2023  
PI: [INVESTIGATOR_266548], MD   
 
 
CONFIDENTIAL  
 
 
38 of 38 
 16. Study Assessment Table  
 
Study procedures Visit  
1 Visit  
2 Follow-Up  
(after Visit [ADDRESS_324532] -guided bx)   
7 days * 
(+0-3d)  3 months  
(±14d)  6 months  
(±30d)  12 months  
(±30d)  
Informed consent  1      
Inclusion/exclusion criteria  [ADDRESS_324533]  (optional)   SOC       
Radiology review  1      
Pathology review    1 (review Visit 2 tissue)  
CT scan (chest)  SOC    SOC  SOC  SOC  
Navigation bronchoscopy (randomized)   SOC      
CT-guided biopsy (randomized)   SOC      
 
* Between [ADDRESS_324534] -guided biopsy (i.e. the standard of care 
procedure performed during Visit 2), e ach patient will subsequently receive a t least one follow-up contact [CONTACT_266610]  (or by [CONTACT_266611]) .  
 
 
 
 
 
 